337 related articles for article (PubMed ID: 27157621)
1. The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment.
Turpin J; Ling C; Crosby EJ; Hartman ZC; Simond AM; Chodosh LA; Rennhack JP; Andrechek ER; Ozcelik J; Hallett M; Mills GB; Cardiff RD; Gray JW; Griffith OL; Muller WJ
Oncogene; 2016 Nov; 35(47):6053-6064. PubMed ID: 27157621
[TBL] [Abstract][Full Text] [Related]
2. An ErbB2 splice variant lacking exon 16 drives lung carcinoma.
Smith HW; Yang L; Ling C; Walsh A; Martinez VD; Boucher J; Zuo D; Sokol ES; Pavlick DC; Frampton GM; Chmielecki J; Jones LM; Roux PP; Lockwood WW; Muller WJ
Proc Natl Acad Sci U S A; 2020 Aug; 117(33):20139-20148. PubMed ID: 32727899
[TBL] [Abstract][Full Text] [Related]
3. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity.
Sriram R; Lo V; Pryce B; Antonova L; Mears AJ; Daneshmand M; McKay B; Conway SJ; Muller WJ; Sabourin LA
Breast Cancer Res; 2015 Jan; 17(1):7. PubMed ID: 25592291
[TBL] [Abstract][Full Text] [Related]
4. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.
Landis MD; Seachrist DD; Montañez-Wiscovich ME; Danielpour D; Keri RA
Oncogene; 2005 Aug; 24(33):5173-90. PubMed ID: 15897883
[TBL] [Abstract][Full Text] [Related]
6. Bcl3 selectively promotes metastasis of ERBB2-driven mammary tumors.
Wakefield A; Soukupova J; Montagne A; Ranger J; French R; Muller WJ; Clarkson RW
Cancer Res; 2013 Jan; 73(2):745-55. PubMed ID: 23149915
[TBL] [Abstract][Full Text] [Related]
7. Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
Peng M; Ball-Kell SM; Tyner AL
Cell Death Dis; 2015 Aug; 6(8):e1848. PubMed ID: 26247733
[TBL] [Abstract][Full Text] [Related]
8. The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis.
Wellberg EA; Johnson S; Finlay-Schultz J; Lewis AS; Terrell KL; Sartorius CA; Abel ED; Muller WJ; Anderson SM
Breast Cancer Res; 2016 Dec; 18(1):131. PubMed ID: 27998284
[TBL] [Abstract][Full Text] [Related]
9. Cell type of origin as well as genetic alterations contribute to breast cancer phenotypes.
Bhagirath D; Zhao X; West WW; Qiu F; Band H; Band V
Oncotarget; 2015 Apr; 6(11):9018-30. PubMed ID: 25940703
[TBL] [Abstract][Full Text] [Related]
10. Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling.
Bancovik J; Moreira DF; Carrasco D; Yao J; Porter D; Moura R; Camargo A; Fontes-Oliveira CC; Malpartida MG; Carambula S; Vannier E; Strauss BE; Wakamatsu A; Alves VA; Logullo AF; Soares FA; Polyak K; Belizário JE
BMC Cancer; 2015 Feb; 15():70. PubMed ID: 25879571
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC-1beta promotes mammary gland tumorigenesis.
Deblois G; Chahrour G; Perry MC; Sylvain-Drolet G; Muller WJ; Giguère V
Cancer Res; 2010 Dec; 70(24):10277-87. PubMed ID: 20961995
[TBL] [Abstract][Full Text] [Related]
12. Mammary tumor formation and metastasis evoked by a HER2 splice variant.
Alajati A; Sausgruber N; Aceto N; Duss S; Sarret S; Voshol H; Bonenfant D; Bentires-Alj M
Cancer Res; 2013 Sep; 73(17):5320-7. PubMed ID: 23867476
[TBL] [Abstract][Full Text] [Related]
13. miR-155 downregulates ErbB2 and suppresses ErbB2-induced malignant transformation of breast epithelial cells.
He XH; Zhu W; Yuan P; Jiang S; Li D; Zhang HW; Liu MF
Oncogene; 2016 Nov; 35(46):6015-6025. PubMed ID: 27065318
[TBL] [Abstract][Full Text] [Related]
14. Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes.
Gatza ML; Kung HN; Blackwell KL; Dewhirst MW; Marks JR; Chi JT
Breast Cancer Res; 2011 Jun; 13(3):R62. PubMed ID: 21672245
[TBL] [Abstract][Full Text] [Related]
15. ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions.
Spangenberg C; Lausch EU; Trost TM; Prawitt D; May A; Keppler R; Fees SA; Reutzel D; Bell C; Schmitt S; Schiffer IB; Weber A; Brenner W; Hermes M; Sahin U; Türeci O; Koelbl H; Hengstler JG; Zabel BU
Cancer Res; 2006 Apr; 66(7):3715-25. PubMed ID: 16585198
[TBL] [Abstract][Full Text] [Related]
16. β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression.
Schade B; Lesurf R; Sanguin-Gendreau V; Bui T; Deblois G; O'Toole SA; Millar EK; Zardawi SJ; Lopez-Knowles E; Sutherland RL; Giguère V; Kahn M; Hallett M; Muller WJ
Cancer Res; 2013 Jul; 73(14):4474-87. PubMed ID: 23720052
[TBL] [Abstract][Full Text] [Related]
17. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
[TBL] [Abstract][Full Text] [Related]
18. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
19. ErbB2-positive mammary tumors can escape PI3K-p110α loss through downregulation of the Pten tumor suppressor.
Simond AM; Rao T; Zuo D; Zhao JJ; Muller WJ
Oncogene; 2017 Oct; 36(43):6059-6066. PubMed ID: 28783168
[TBL] [Abstract][Full Text] [Related]
20. c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion.
Jiao X; Katiyar S; Willmarth NE; Liu M; Ma X; Flomenberg N; Lisanti MP; Pestell RG
J Biol Chem; 2010 Mar; 285(11):8218-26. PubMed ID: 20053993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
